Table 1 DIPG and GBM cell models used in studies
From: Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Article Model Name | DIPG-6 | DIPG-17 | DIPG-24 | SF-8628 | CHLA-200 |
Official Name | SU-DIPG-VI | SU-DIPG-XVII | SU-DIPG-24 | SF8628 | CHLA-200 |
Accession ID | CVCL_IT40 | N/A | N/A | CVCL_IT46 | CVCL_M147 |
IL13Rα2 Status | IL13Rα2-High | IL13Rα2-High | IL13Rα2-Low | IL13Rα2-High | IL13Rα2-High |
Model Type | Neurosphere Culture (suspension) | Neurosphere Culture (suspension) | Neurosphere Culture (generally adherent) | Cell Line (adherent) | Cell Culture (adherent) |
Growth Media | Complete TSM | Complete TSM | Complete TSM | DMEM + 1% P/S + 10% FBS | IMDM + 1% P/S + 20% FBS + 4 mM L-Glut + 1× ITS |
Age at diagnosis (years) | 7 | 8 | 6 | 5 | 12 |
Gender | Female | Male | Female | Female | Male |
Histology | HGG | DIPG | DIPG | DIPG | GBM |
H3 status | H3.3K27M | H3.3K27M | H3.3K27M | H3.3K27M | Unknown |
Grade | III | IV | IV | IV | IV |
Origin | Pons | Pons | Pons | Unknown | Parietal lobe |
Treatment | XRT + vorinostat | XRT + bevacizumab; panobinostat—> XRT—> everolimus | XRT + bevacizumab | Unknown | XRT + chemotherapy |
Survival (months) | 6 | 13 | 8 | Unknown | Unknown |
Tissue Source | autopsy | autopsy | autopsy | surgical biopsy | autopsy |
Material Source | Monje Lab | Monje Lab | Monje Lab | EMD Millipore | COG Repository |
PMID | 25939062[25] | 28823557[47] | 28823557[47] | 23603901[13] | 22120608[54] |